Abstract SAT0223 - Background: Autoimmune and inflammatory mechanisms could play a significant role in the pathogenesis of pulmonary arterial hypertension (PAH), especially in patients with systemic lupus erythematosus (SLE). The effect of immunosuppressive therapy in the treatment of SLE-associated PAH (SLE-PAH) has not been fully investigated in a large cohort previously. Objectives: We aimed to review the clinical outcomes in patients with SLE-PAH cohort treated with intensive immunosuppressive therapy with or without PAH-targeted therapy. Methods: In this single-center cohort study, 126 patients with SLE-PAH were consecutively enrolled between May 2006 through December 2015. All patients were performed right heart catheriazation to confirm the diagnosis of PAH, and all received intensive immunosuppressive therapy including combination of high-dose glucocorticosteroids and immunosuppressants, such as cyclophosphamide, mycophenolate and calcineurin inhibitors. Baseline demographics, clinical features, laboratory findings, hemodynamic measurements and treatment were analyzed. Kaplan-Meier curves and Cox proportional hazards regression analysis were used to evaluate the role of intensive immunosuppressive therapy. Results: Of the 126 SLE-PAH patients, eighty-two (65.1%) patients received PAH-targeted therapy at baseline. Demographic and clinical characteristics were shown in Table 1 . Survival analysis indicated that responders had a better survival than nonresponders in both with and without PAH-targeted therapy groupPatients with a shorter SLE disease duration (p=0.009) and better baseline pulmonary hemodynamics (mean pulmonary arterial pressure, pulmonary vascular resistance and Cardiac index, p<0.001) were more likely to benefit from immunosuppressive therapy ( Table 1) .
Conclusions:
Intensive immunosuppressive therapy markedly improved the long-term outcomes of SLE patients with PAH, especially in the early stage of PAH. Background: CC-220 is a cereblon E3 ligase modulatory compound currently in development for the treatment of Systemic Lupus Erythematosus as well as other autoimmune conditions and multiple myeloma. As a high affinity ligand for cereblon, CC-220 administration results in significant reductions in ikaros (IKZF1) and aiolos (IKZF3), transcription factors which are genetically linked to SLE risk, and are overexpressed in the peripheral blood of SLE patients compared to healthy controls. Objectives: To describe the pharmacokinetics (PK), pharmacodynamics (PD), and the PK-PD relationship of CC-220 in subjects with SLE. Methods: CC-220-SLE-001 is a randomized, double-blinded, placebo-controlled, phase 2a dose escalation study to investigate the safety, PK, PD, and efficacy of CC-220 in patients with SLE. Forty-two (42) adult SLE subjects fulfilling SLE ACR criteria, having a history of SLE for ≥6 months and a baseline Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score ≥4 were randomized to placebo or 1 of 4 escalating doses of CC-220 (0.3 mg QOD, 0.3 mg QD, 0.6/0.3 mg alternating QD, or 0.6 mg QD). 1 with a deactivating coding variant conferring significant protection against multiple immune-mediated disorders including systemic lupus erythematosus (SLE).
SAT0225 CEREBLON MODULATOR CC-220 DECREASES NAÏVE AND MEMORY B CELLS AND PLASMACYTOID DENDRITIC CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS: EXPOSURE-RESPONSE RESULTS FROM A PHASE 2A PROOF OF CONCEPT STUDY
2 Selective pharmacologic inhibition of Tyk2 has proven daunting, given the high degree of similarity among JAK catalytic domains. Using a novel approach, we have developed BMS-986165, a highly selective and potent small molecule inhibitor, which blocks receptor-mediated Tyk2 activation by stabilizing the regulatory pseudokinase domain of the protein. Lupus-like disease is strongly inhibited in NZB/W mice treated with BMS-986165. Together, these data establish Tyk2 as a highly promising therapeutic target for SLE. Objectives: We report the first evidence of safety, pharmacokinetics (PK), target engagement (TE), and pharmacodynamic activity (PD) of BMS-986165, a novel inhibitor of Tyk2. Methods: Safety, PK, TE, and PD were assessed in a randomized, double-blind, single and multiple ascending dose study of 108 (83 active: 25 placebo) healthy participants (NCT02534636). Target engagement was assessed by an ex vivo assay, IL-12 and IL-18 induced IFNγ production. Roferon-A was administered to assess in vivo pharmacodynamic effects of BMS-986165 on physiological manifestations of IFN exposure and on IFN-regulated gene (IRG) expression. Results: BMS-986165 was safe and overall well-tolerated. There were no serious adverse events and the frequency of non-serious adverse events were similar in the active (75%) and placebo (76%) groups. The most frequently reported adverse events by preferred term were headache (23% active versus 28% placebo), nausea (12% active versus 8% placebo), rash (12% active versus 8% placebo), and upper respiratory tract infection (11% active versus 12% placebo). After oral administration, BMS-986165 was rapidly absorbed and exhibited an apparent elimination half-life of 8-15 hours. Modest accumulation (1.4x-1.9x) was observed after multiple dosing. BMS-986165 inhibited IL-12/IL-18-induced IFNγ production in ex vivo assays in a dose and concentration dependent manner. 
